NCT05061537 - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 20, 2021

Primary Completion Date

October 14, 2022

Study Completion Date

October 14, 2022

Conditions

Renal Cell CancerMelanomaNon-Small-Cell Lung CancerHepatocellular CancerBladder CancerSarcomaHead and Neck CancerColorectal CancerOvarian CancerSquamous Cell Carcinoma

Interventions

BIOLOGICAL

PF-07263689

Genetically engineered oncolytic vaccinia virus

BIOLOGICAL

Sasanlimab

A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/ PD-L2

Trial Locations (3)

10032

Columbia University Medical Center, New York

CUMC Research Pharmacy, New York

91010

City of Hope, Duarte